<DOC>
	<DOCNO>NCT02244021</DOCNO>
	<brief_summary>A pilot phase II study brentuximab vedotin pre-ASCT induction therapy relapsed/refractory Hodgkin 's lymphoma patient non-responding IGEV salvage treatment .</brief_summary>
	<brief_title>A Pilot Phase II Study With BRENTUXIMAB VEDOTIN Pre-ASCT Induction Therapy Relapsed/Refractory Hodgkin 's Lymphoma Patients Non Responding IGEV Salvage Treatment</brief_title>
	<detailed_description>Brentuximab vedotin emerge active single-agent treatment relapse refractory HL . Some patient n't reach complete response salvage treatment IGEV ( ifosfamide , gemcitabine , vinorelbine ) remain PET positive idea treat subset patient brentuximab vedotin aim achieve complete remission transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Classical Hodgkin Lymphoma accord WHO classification 2 . Histologically confirm CD30+ HL diagnosis 3 . Patients first line salvage therapy 4 . FDGPET positivity two cycle IGEV treatment 5 . PBPCs collect first second IGEV cycle 6 . Age≥ 18 year 7 . ECOG PS 02 8 . Life expectancy &gt; 6 month . 9 . Written inform consent 10 . Patients available periodic blood sampling , studyrelated assessment management toxicity 11 . Females childbearing potential must negative βHCG pregnancy test result ( pregnancy test perform screening day 1 cycle 1 prior brentuximab vedotin treatment ) . 12 . Female patient either postmenopausal least 1 year screen visit surgically sterile childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 6 month last dose study drug , agree completely abstain heterosexual intercourse . 13 . Male patient , even surgically sterilize , ( i.e. , status post vasectomy ) agree practice effective barrier contraception entire study period 6 month last dose study drug , agree completely abstain heterosexual intercourse . 14 . Required baseline laboratory data : Absolute neutrophil count ≥ 1500/µl , Platelet count ≥ 75.000/ µl , Haemoglobin must ≥ 8 g/dL , Serum bilirubin ≤ 1.5 time ULN , Serum creatinine &lt; 2.0 mg/dL and/or creatinine clearance calculate creatinine clearance &gt; 40 mL/minute , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time ULN 1 . Peripheral neuropathy &gt; Grade 1 2 . Histologic diagnosis different Hodgkin Lymphoma 3 . First line treatment BEACOPP 4 . Compressive symptom cause presence Lymphoma 5 . Patients treat previously antiCD30 antibody . 6 . Known hypersensitivity recombinant protein , murine protein , excipients contain brentuximab vedotin formulation . 7 . Known human immunodeficiency virus ( HIV ) positive 8 . Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection 9 . Diagnosed treat another malignancy within 3 year first dose previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . 10 . Patients known history follow cardiovascular condition : Myocardial infarction within 2 year randomization , New York Heart Association ( NYHA ) Class III IV heart failure , Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , electrocardiographic evidence acute ischemia active conduction system abnormality , Recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % 11 . Patients know active viral , bacterial , fungal infection require treatment antimicrobial therapy within 2 week prior first dose brentuximab vedotin . 12 . Patients know active Grade 3 high viral , bacterial , fungal infection within 2 week prior first dose brentuximab vedotin . 13 . Patients know cerebral/meningeal disease ( HL etiology ) , include sign symptom Progressive Multifocal Leukoencephalopathy 14 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . 15 . Symptomatic neurologic disease compromise normal activity daily live require medication . 16 . Patients pregnant , lactate breastfeeding . 17 . Patients complete prior treatment chemotherapy and/or investigational agent within least 5 halflives last dose prior treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HD</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>RELAPSED-REFRACTORY</keyword>
</DOC>